Trial Profile
The Effect of OC000459 on Eosinophilic Airway Inflammation and Asthma Control in Subjects With Refractory Eosinophilic Asthma: a Randomised, Double-blind, Placebo Controlled Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Mar 2020
Price :
$35
*
At a glance
- Drugs Timapiprant (Primary)
- Indications Asthma
- Focus Proof of concept; Therapeutic Use
- Sponsors Atopix Therapeutics
- 08 Jan 2019 Status changed from recruiting to completed.
- 21 Mar 2018 Planned End Date changed from 1 Sep 2017 to 1 Jun 2018.
- 21 Mar 2018 Planned primary completion date changed from 1 Sep 2017 to 1 Jun 2018.